Biocompatibility isn’t a box to check; it’s a continuous thread that runs from early material selection through commercial release. USP <87> Biological Reactivity Tests—In Vitro provide a fast, ethical, and sensitive cytotoxicity screen for materials and finished plastics/elastomers, helping teams make confident decisions both during characterization (often prior to, or in lieu of, in vivo testing and/or extractables & leachables (E&L) studies) and later as a release test. At CS Analytical, we execute USP <87> aligned methods and help you map results into the broader packaging qualification strategy.
What USP <87> Evaluates (In Plain Terms)
USP <87> assesses whether a material (or its extract) shows cytotoxic effects on mammalian cell cultures under controlled conditions (e.g., direct contact, agar diffusion, or elution). Results are graded for reactivity, with system-suitability controls ensuring data integrity. This makes <87> an ideal screen to quickly flag risky chemistries or residues before you invest in longer, more complex programs.
Where USP <87> Fits in Your Package/Component Strategy
Depending on your dosage form and component, USP <87> is referenced, directly or by practice, across multiple USP chapters governing plastics and elastomers. CS Analytical’s recommended applications include:
- During characterization (pre-E&L / pre-in vivo):
Use <87> to screen candidate resins, compounding variations, process changes, and finished components (stoppers, plungers, tips, bottles, blisters, etc.). This can reduce animal testing and sharpen the focus of subsequent USP <1663>/<1664> E&L work. - As a complementary/release test:
After materials and package systems are locked, <87> can be applied as a periodic release or change-control check—particularly for elastomeric components qualified under USP <381> and guided by USP <1381> (and, functionally, USP <382> for performance where applicable).
How Specific Chapters Point You to USP <87>
- Elastomers — USP <381> & USP <1381>:
<381> sets baseline chemical and biological reactivity requirements for elastomeric components used with injectables. USP <1381> supplements <381> with deeper guidance on assessing elastomeric materials. In practice, USP <87> is used to establish in vitro biological reactivity during selection/qualification and is an ongoing screen post-characterization through commercialization for component material release. - Plastics — USP <661.1> (Materials) & USP <661.2> (Systems):
<661.1> covers plastic materials of construction; <661.2> covers the composite plastic packaging system (e.g., bottle + closure + seal). For most non-oral/non-topical dosage forms, USP <87> cytotoxicity testing is required as part of the biocompatibility expectations in these chapters, making <87> a critical screen both during material characterization and for final system qualification (and by extension usable for release when risk-based programs call for it).
Tip: Oral and topical dosage forms generally do not require USP <87> under <661.1>/<661.2>, while other dosage forms do; a nuance our team addresses in study design and quotations.
Why Teams Choose USP <87> Early (and Often)
- Speed & sensitivity: Quickly differentiate acceptable vs. risky materials/finishes and prioritize deeper E&L or in vivo only when justified.
- Regulatory alignment: <87> is a recognized in vitro cytotoxicity standard widely applied in packaging and device materials strategies, aligning with the 661.1/661.2 modernization timeline (Dec 1, 2025).
- Lifecycle utility: The same method is generally deployed later as a release or change-control check, supporting cGMP continuity for elastomers and plastics.
How CS Analytical Executes USP <87>—and Connects the Dots
We help you choose the right method (direct contact, agar diffusion, or elution) for your geometry and risk profile; set appropriate extraction conditions; run mammalian cell assays with robust controls; and deliver regulatory-ready reports. Just as important, we place results into context—bridging to elastomer requirements (USP <381> / guidance <1381>) or plastics programs (USP <661.1>/<661.2>), and aligning with your E&L strategy (USP <1663>/<1664>) when needed.
Quick Links (CS Analytical Services)
- USP <87> Biological Reactivity (In Vitro): https://csanalytical.com/comprehensive-complementary-solutions/usp-biological-reactivity/
- USP <381> Elastomers: https://csanalytical.com/physicochemical-testing/usp-elastomers/
- USP <1381> Elastomeric Materials—Guidance: https://csanalytical.com/usp-chapters-specific-container-package-system-testing/
- USP <661.1> Plastic Materials of Construction: https://csanalytical.com/physicochemical-testing/usp-plastic-materials/
- USP <661.2> Plastic Packaging Systems: https://csanalytical.com/physicochemical-testing/usp-661-2-plastic-packaging-systems/
- FAQ: When does <87> apply under 661.1/661.2? https://csanalytical.com/usp-661-1-and-usp-661-2-frequently-asked-questions/

